- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1613-7671
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Updated Austrian treatment algorithm in HER2+ metastatic breast cancer ; volume:134 ; number:1-2 ; day:28 ; month:1 ; year:2022 ; pages:63-72 ; date:1.2022
Wiener klinische Wochenschrift ; 134, Heft 1-2 (28.1.2022), 63-72, 1.2022
- Creator
-
Bartsch, Rupert
Gampenrieder, Simon Peter
Rinnerthaler, Gabriel
Petru, Edgar
Egle, Daniel
Petzer, Andreas
Balic, Marija
Pluschnig, Ursula
Sliwa, Thamer
Singer, Christian
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s00508-021-01987-9
- URN
-
urn:nbn:de:101:1-2022051220411123924185
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:37 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Bartsch, Rupert
- Gampenrieder, Simon Peter
- Rinnerthaler, Gabriel
- Petru, Edgar
- Egle, Daniel
- Petzer, Andreas
- Balic, Marija
- Pluschnig, Ursula
- Sliwa, Thamer
- Singer, Christian
- SpringerLink (Online service)
Other Objects (12)
Updated Austrian treatment algorithm for metastatic triple-negative breast cancer
Austrian treatment algorithms in HER2-positive metastatic breast cancer: a 2022 update
Landscape of HER2-low metastatic breast cancer (MBC): results from the Austrian AGMT_MBC-Registry
Targeted therapies for ER+/HER2- metastatic breast cancer
How We Treat HER2-Positive Metastatic Breast Cancer
ASCO 2019: highlights in HER2-positive metastatic breast cancer
ASCO 2018: highlights in HER2-positive metastatic breast cancer
Clinicopathological features of HER2 positive metastatic colorectal cancer and survival analysis of anti-HER2 treatment
Real-world treatment in patients with HER2+ metastatic breast cancer : Treatment decisions in HER2+ mBC
Molecular landscape and efficacy of HER2-targeted therapy in patients with HER2-mutated metastatic breast cancer
Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer
HER2-targeted therapy influences CTC status in metastatic breast cancer
Updated Austrian treatment algorithm for metastatic triple-negative breast cancer
Austrian treatment algorithms in HER2-positive metastatic breast cancer: a 2022 update
Landscape of HER2-low metastatic breast cancer (MBC): results from the Austrian AGMT_MBC-Registry
Targeted therapies for ER+/HER2- metastatic breast cancer
How We Treat HER2-Positive Metastatic Breast Cancer
ASCO 2019: highlights in HER2-positive metastatic breast cancer
ASCO 2018: highlights in HER2-positive metastatic breast cancer
Clinicopathological features of HER2 positive metastatic colorectal cancer and survival analysis of anti-HER2 treatment
Real-world treatment in patients with HER2+ metastatic breast cancer : Treatment decisions in HER2+ mBC
Molecular landscape and efficacy of HER2-targeted therapy in patients with HER2-mutated metastatic breast cancer
Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer
HER2-targeted therapy influences CTC status in metastatic breast cancer
Updated Austrian treatment algorithm for metastatic triple-negative breast cancer
Austrian treatment algorithms in HER2-positive metastatic breast cancer: a 2022 update
Landscape of HER2-low metastatic breast cancer (MBC): results from the Austrian AGMT_MBC-Registry
Targeted therapies for ER+/HER2- metastatic breast cancer
How We Treat HER2-Positive Metastatic Breast Cancer
ASCO 2019: highlights in HER2-positive metastatic breast cancer
ASCO 2018: highlights in HER2-positive metastatic breast cancer
Clinicopathological features of HER2 positive metastatic colorectal cancer and survival analysis of anti-HER2 treatment
Real-world treatment in patients with HER2+ metastatic breast cancer : Treatment decisions in HER2+ mBC
Molecular landscape and efficacy of HER2-targeted therapy in patients with HER2-mutated metastatic breast cancer
Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer